Quick Takeaways
- Fairmount Funds Management LLC filed SCHEDULE 13G/A for Inhibikase Therapeutics, Inc. Common Stock, par value $0.001 per share (IKT).
- Disclosed ownership: 9.9%.
- Date of event: 31 Dec 2024.
Fairmount Funds Management LLC - 31 Dec 2024 SCHEDULE 13G/A Report for Inhibikase Therapeutics, Inc. Common Stock, par value $0.001 per share (IKT)
- Filing Manager
- Fairmount Funds Management LLC
- Reporting Manager
- Fairmount Funds Management LLC
- Symbol
- IKT
- Shares outstanding
- 70,894,697 shares
- Disclosed Ownership
- 7,018,575 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 15:45:06 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 17 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Fairmount Funds Management LLC disclosed 9.9% ownership in Inhibikase Therapeutics, Inc. Common Stock, par value $0.001 per share (IKT) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 15:45.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 9.9% | 7,018,575 | 0 | 7,018,575 | /s/ Peter Harwin | Peter Harwin, Managing Member | |
| Fairmount Healthcare Fund II L.P. | 9.9% | 7,018,575 | 0 | 7,018,575 | /s/ Peter Harwin | Peter Harwin, Member | |
| Peter Harwin | 9.9% | 7,018,575 | 0 | 7,018,575 | /s/ Peter Harwin | Peter Harwin | |
| Tomas Kiselak | 9.9% | 7,018,575 | 0 | 7,018,575 | /s/ Tomas Kiselak | Tomas Kiselak |